COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #177
Source   PDF   Share   Tweet
See all 181 studies
11/19
Positive
Late treatment study
Falcone et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa563 (Peer Reviewed)
Role of low-molecular weight heparin in hospitalized patients with SARS-CoV-2 pneumonia: a prospective observational study
Prospective observational study of 315 hospitalized patients in Italy showing 65% lower mortality with HC Q. The median treatment delay was 6 days for survivors and 6.5 days for non-survivors. Mortality relative risk:
RR 0.35, p = 0.2, propensity score matched
RR 0.75, p = 0.36, multivariate Cox regression
RR 0.43, p < 0.001, univariate Cox regression
death, ↓65.0%, p=0.20, PSM
death, ↓25.0%, p=0.36, multivariate Cox regression
death, ↓57.0%, p<0.001, univariate Cox regression
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.
Submit